Apixaban News and Research

RSS
Oral Eliquis receives FDA approval for treatment of clots in non-valvular atrial fibrillation patients

Oral Eliquis receives FDA approval for treatment of clots in non-valvular atrial fibrillation patients

Studies examine current treatment standards for patients with clotting disorders

Studies examine current treatment standards for patients with clotting disorders

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Pfizer, Bristol-Myers Squibb announce data from ELIQUIS clinical trial on AF

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

EMA CHMP adopts positive opinion for ELIQUIS to prevent stroke, systemic embolism in NVAF patients

Apixaban offers minor added benefit for adult patients after hip replacement

Apixaban offers minor added benefit for adult patients after hip replacement

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

FDA extends action date for Bristol-Myers Squibb, Pfizer's Eliquis NDA

FDA extends action date for Bristol-Myers Squibb, Pfizer's Eliquis NDA

New blood-thinning drugs likely to replace Coumadin for patients with non-valvular AF

New blood-thinning drugs likely to replace Coumadin for patients with non-valvular AF

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

FDA panel votes 9-2 in favor of new blood thinner drug

FDA panel votes 9-2 in favor of new blood thinner drug

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Apixaban superior to warfarin in preventing stroke and systemic embolism

Apixaban superior to warfarin in preventing stroke and systemic embolism